Alnylam Pharmaceuticals To Present HELIOS-B Phase 3 Study Results Of Vutrisiran At ESC Congress 2024; Announces Topline Results Demonstrating Significant Reduction In Mortality And Cardiovascular Events
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals will present the HELIOS-B Phase 3 study results of Vutrisiran at the ESC Congress 2024. The topline results show a significant reduction in mortality and cardiovascular events. The company will host a conference call and investor webcast on August 30, 2024.
August 07, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals will present the HELIOS-B Phase 3 study results of Vutrisiran at the ESC Congress 2024, showing significant reduction in mortality and cardiovascular events. A conference call and investor webcast will be held on August 30, 2024.
The significant reduction in mortality and cardiovascular events from the HELIOS-B Phase 3 study results is a positive development for Alnylam Pharmaceuticals. This could lead to increased investor confidence and a potential rise in stock price. The upcoming conference call and investor webcast will likely provide further details, potentially driving short-term interest and stock movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100